Authors: Cady, RK Sheftell, F Lipton, RB Kwong, WJ O'Quinn, S

Citation: Rk. Cady et al., Economic implications of early treatment of migraine with sumatriptan tablets, CLIN THER, 23(2), 2001, pp. 284-291

Authors: Sheftell, F Dodick, D Cady, R

Citation: F. Sheftell et al., Direct-to-consumer advertising of OTC agents under current FTC regulations: Concerns and comment, HEADACHE, 41(6), 2001, pp. 534-536

Authors: Cady, RK Sheftell, F Lipton, RB O'Quinn, S Jones, M Putnam, DG Crisp, A Metz, A McNeal, S

Citation: Rk. Cady et al., Effect of early intervention with sumatriptan on migraine pain: Retrospective analyses of data from three clinical trials, CLIN THER, 22(9), 2000, pp. 1035-1048

Authors: Sheftell, F O'Quinn, S Watson, C Pait, D Winter, P

Citation: F. Sheftell et al., Low migraine headache recurrence with naratriptan: Clinical parameters related to recurrence, HEADACHE, 40(2), 2000, pp. 103-110

Authors: Sheftell, F Rapoport, A Weeks, R Walker, B Gammerman, I Baskin, S

Citation: F. Sheftell et al., Montelukast in the prophylaxis of migraine: A potential role for leukotriene modifiers, HEADACHE, 40(2), 2000, pp. 158-163

Authors: Lipton, RB Stewart, WF Ryan, RE Saper, J Silberstein, S Sheftell, F

Citation: Rb. Lipton et al., Limitations of acetaminophen, aspirin, and caffeine in alleviating migraine - In reply, ARCH NEUROL, 55(12), 1998, pp. 1590-1590